A Phase 3 interventional study of 5% Minoxidil and 2% Minoxidil in Alopecia, sponsored by Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.. Completed at 12 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-22.
Sponsored by Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.
Among the 31 studies testing minoxidil in Alopecia, this one is the 4th largest by enrollment, is one of 2 that started in 2010, is one of 8 in phase 3, and was the 4th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:
Kasr El Aini Hospital · Sites in Egypt
Ages 18–50 · Men only · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–40 · Women only
Sohag University · Sites in Egypt
Ages 15–60 · Women only · Healthy volunteers
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+ · Women only
Eurofarma Laboratorios S.A. · Sites in Brazil
Ages 18–60 · Men only
By country, each count listing its studies:
Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2003; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 322 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 60 across the 31 interventional studies. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Johnson & Johnson has 3 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
1 of the studies testing minoxidil in Alopecia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05778825Memorial Sloan Kettering Cancer CenterA Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing minoxidil in Alopecia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a year-long clinical trial to evaluate the effectiveness and safety in women with Female Pattern Hair Loss (FPHL), comparing a new 5% minoxidil topical foam (MTF) formulation applied once a day versus the 2% minoxidil topical solution (MTS) applied twice a day.
This clinical trial uses an objective measurement called Target Area Hair Count (TAHC) to evaluate if there is a change in the number of hairs in the area being examined after using the product for 24 weeks (and also after using the product for 12 Weeks and for 52 weeks).
This trial will determine if the benefit of using either study product outweighs the risks.
This is a phase 3, two-arm, randomized, active-controlled, multi-center, 52-week, parallel design trial to evaluate the efficacy and safety in women with Female Pattern Hair Loss (FPHL), comparing the new 5% minoxidil topical foam (MTF) formulation versus the 2% minoxidil topical solution (MTS) formulation.
This clinical trial is designed to compare the risk/benefit profile of the 5% MTF formulation applied once a day versus the 2% MTS applied twice a day (BID), using objective efficacy measures and safety assessments.
Study centers will screen a sufficient number of participants so that a minimum of 300 female participants with FPHL will be enrolled, to ensure 270 to complete. There will be at least 16 participants enrolled per center at multiple centers located across the US and globally. Approximately 300 participants will be randomly assigned in a 1:1 ratio to use either 5% MTF or 2% MTS, for 52 weeks for efficacy and safety evaluations.
Participants meeting the inclusion criteria will be randomly assigned in the order of their enrollment at each site. The signing of the informed consent and assignment of a participant number to a subject shall constitute enrollment.
During the trial following enrollment at Baseline, participants will return to the study site at regular intervals for safety assessments, adverse events monitoring, and compliance assessments. At the Week 12, 24, and Week 52 visits TAHC will be evaluated for efficacy analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5% Minoxidil Topical Foam
Drug: 5% Minoxidil
2% Minoxidil Topical Solution
Drug: 2% Minoxidil
half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
Also known as: ROGAINE®
Target Area Hair Count (TAHC)
Number of hairs in the area being examined as measured by macrophotography.
Time frame: Baseline to Week 24
Target Area Hair Count (TAHC)
Number of hairs in the area being examined as measured by macrophotography
Time frame: Baseline to Week 12
Target Area Hair Count (TAHC)
Number of hairs in the area being examined as measured by macrophotography.
Time frame: Baseline to Week 52
| Milestone | 2% MTS | 5% MTF |
|---|---|---|
| Started | 161 | 161 |
| Completed | 137 | 130 |
| Not completed | 24 | 31 |
| Withdrew: Lost to follow-up | 8 | 9 |
| Withdrew: Adverse event | 6 | 4 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Withdrawal by subject | 7 | 16 |
| Withdrew: Pregnancy | 0 | 1 |
Number of hairs in the area being examined as measured by macrophotography.
| hairs per centimeter squared | 2% MTS | 5% MTF |
|---|---|---|
| Baseline | 167.3 ± 55.0 | 169.7 ± 58.6 |
| Week 24 | 192.8 ± 57.0 | 194.4 ± 64.7 |
| Change from Baseline to Week 24 | 23.8 ± 24.7 | 23.7 ± 22.9 |
Number of hairs in the area being examined as measured by macrophotography
| hairs per centimeter squared | 2% MTS | 5% MTF |
|---|---|---|
| Baseline | 167.3 ± 55.0 | 169.7 ± 58.6 |
| Week 12 | 190.7 ± 56.9 | 191.8 ± 62.6 |
| Change from Baseline to Week 12 | 22.5 ± 22.8 | 24.9 ± 26.0 |
Number of hairs in the area being examined as measured by macrophotography.
| hairs per centimeter squared | 2% MTS | 5% MTF |
|---|---|---|
| Baseline | 167.3 ± 55.0 | 169.7 ± 58.6 |
| Week 52 | 189.1 ± 55.8 | 186.9 ± 61.1 |
| Change from Baseline to Week 52 | 19.4 ± 21.5 | 18.1 ± 23.4 |
Non-serious events are listed at a 2.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2% MTS | — | 8/161 (5%) | 118/161 (73.3%) |
| 5% MTF | — | 2/161 (1.2%) | 109/161 (67.7%) |
| Event | 2% MTS | 5% MTF |
|---|---|---|
| Anal AbscessInfections and infestations | 1/161 | 0/161 |
| InfluenzaInfections and infestations | 1/161 | 0/161 |
| Angina PectorisCardiac disorders | 1/161 | 0/161 |
| Abdominal PainGastrointestinal disorders | 1/161 | 0/161 |
| Bile Duct StoneHepatobiliary disorders | 1/161 | 0/161 |
| Wrist FractureInjury, poisoning and procedural complications | 0/161 | 1/161 |
| Metastatic NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/161 | 0/161 |
| AnxietyPsychiatric disorders | 0/161 | 1/161 |
| MenometrorrhagiaReproductive system and breast disorders | 1/161 | 0/161 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/161 | 0/161 |
| Event | 2% MTS | 5% MTF |
|---|---|---|
| NasopharyngitisInfections and infestations | 22/161 | 23/161 |
| Weight increasedInvestigations | 14/161 | 20/161 |
| Upper respiratory tract infectionInfections and infestations | 8/161 | 16/161 |
| HeadacheNervous system disorders | 16/161 | 9/161 |
| SinusitisInfections and infestations | 12/161 | 10/161 |
| Urinary tract infectionInfections and infestations | 3/161 | 8/161 |
| BronchitisInfections and infestations | 2/161 | 8/161 |
| Back painMusculoskeletal and connective tissue disorders | 5/161 | 7/161 |
| Procedural painInjury, poisoning and procedural complications | 6/161 | 4/161 |
| DiarrhoeaGastrointestinal disorders | 2/161 | 5/161 |
Intent to Treat (ITT) population defined as all participants randomly assigned to a treatment group who received dispensed investigational product.
| Age, Categorical(Participants) | 2% MTS | 5% MTF | Total |
|---|---|---|---|
| <=18 years | 1 | 1 | 2 |
| Between 18 and 65 years | 134 | 129 | 263 |
| >=65 years | 26 | 31 | 57 |
| Sex: Female, Male(Participants) | 2% MTS | 5% MTF | Total |
|---|---|---|---|
| Female | 161 | 161 | 322 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 2% MTS | 5% MTF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 4 | 7 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 4 | 5 | 9 |
| White | 149 | 141 | 290 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 6 | 10 |
The record gives a start of Jun 2010, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 2 years 2 months after primary completion. A results delay was requested in Feb 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Minoxidil
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. →